Drugs / MSRD-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02677636 | ? → Jul 2016 | atopic eczema | Merz North America, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02677610 | ? → Jul 2016 | atopic eczema | Merz North America, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSRD-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02677636 ↗ |
| Route | Topical | “MSRD-100 is a topical gel.” NCT02677610 ↗ |